RTX-1363-S

N/A

Report date: 2025/11/21 17:15:27
NME

Base Information

Drug NameRTX-1363-S
Drug Alias Name[Cu-64]-labeled RTX-1363SCopper-64-labeled RTX-1363SRTX-1363SRTX-1363-S
ClassificationRadiation-emitting products > Nuclides > Copper > 64CuRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionFibroblast activation protein alpha inhibitors
TargetsProlyl endopeptidase FAP
Therapy Area/IndicationsLung NeoplasmsPancreatic NeoplasmsStomach Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesRatio Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesLantheusPharmaLogic Holdings CorpRatio Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLung NeoplasmsPancreatic NeoplasmsStomach Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A